Clinical Trial Update: A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma [Phase 4]

View source ↗

Summary

A Phase 4 randomized trial comparing evening dosing of Xalacom versus Cosopt in glaucoma patients completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glaucoma
• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• Cosopt (dorzolamide/timolol)
• Xalacom (latanoprost/timolol)

Snippet

Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Conditions: Glaucoma, Open Angle, Ocular Hypertension | Phase 4 | Status: COMPLETED